Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history

Transplantation

Volumn 96, Issue 3, 2013, Pages 297-305

  Brattström, Christina ^a   Granath, Fredrik ^a   Edgren, Gustaf ^b,c   Smedby, Karin E ^a   Wilczek, Henryk E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cancer related mortality; Preexisting cancer; Pretransplantation cancer history; Transplantation

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; MORTALITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RISK ASSESSMENT; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; ORGAN TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS;

EID: 84881613247     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829854b7     Document Type: Article

References (46)

1. Hariharan S, Johnson CP, Bresaahan BA, et al. Improved graft survival after renal transplantation in the United States 1988-1996. N Engl J Med 2000; 342: 605.
2. Ojo AO,Meier-Kriesche HU, Hanson JA, et al.Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405.
3. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923.
4. Vajdic CM, Van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125: 1747.
5. Pedotti P, Cardillo M, Rossini G, et al. Incidence of cancer after kidney transplant: results from the north Italy transplant program. Transplantation 2003; 76: 1448.
6. Tremblay F, Fernandes M, Habbab F, et al. Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol 2002; 9: 785.
7. Kirklin JK, Naftel DC, Bourge RC, et al. Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multiinstitutional study. J Thorac Cardiovasc Surg 2003; 125: 881.
8. McDonald SP, Excell L, Livingstone B. In: McDonald S, Chang S, Excell L, eds. ANZDATA Registry Report 2007. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry; 2007.
9. Gross TG, Shiramizu B. Lymphoproliferative disorders and malignancies related to immunodeficiencies. In: Pizzo PA, Poplack DG, eds. Principles & Practice of Pediatric Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006.
10. Adams PL. Long-term patient survival: strategies to improve overall health. Am J Kidney Dis 2006; 47: S65.
11. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80: S254.
12. Ershler WB. Cancer: a disease of the elderly. J Support Oncol 2003; 1: 5.
13. Ershler WB, Longo DL. Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 1997; 89: 189.
14. Repetto L, Venturino A, Fratino L, et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 2003; 39: 870.
15. Girndt M, Köhler H. Waiting time for patients with a history of malignant disease before listing for organ transplantation. Transplantation 2005; 80: S167.
16. Penn I. The effect of immunosuppression on preexisting cancers. Transplantation 1993; 55: 742.
17. Penn I. Evaluation of transplant candidates with preexisting malignancies. Ann Transplant 1997; 2: 14.
18. Kasiske BL, Ramos EL, Gaston MJ, et al. The evaluation of renal transplant candidates: clinical practice guidelines. J Am Soc Nephrol 1995; 6: 1.
19. European Best Practice Guidelines for Renal Transplantation (Part 1). Produced by the EBPG Expert Group on Renal Transplantation. Section I: Evaluation, selection and preparation of the potential transplant recipient. Nephrol Dial Transplant 2000; 15: 3.
20. Chapman JR, Sheil AGR, Disney APS. Recurrence of cancer after renal transplantation. Transplant Proc 2001; 33: 1830.
21. Hanaway MJ, Weber S, Buell JF, et al. Risk for recurrence and death from preexisting cancers after transplantation. Transplant Rev 2005; 19: 151.
22. Kauffmann HM, Cherikh WS, McBride MA, et al. Transplant recipients with a history of malignancy: risk of recurrent and de novo cancers. Transplant Rev 2005; 19: 55.
23. Kauffmann HM. Malignancies in organ transplant recipients. J Surg Oncol 2006; 94: 431.
24. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905.
25. Dantal J, Hourmant M, Cantarovitch D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623.
26. Gallo P, Agozzino L, Angelini A, et al. Causes of late failure after heart transplantation: a ten-year survey. J Heart Lung Transplant 1997; 16: 1113.
27. Sheil AGR, Disney APS, Matthew TH, et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383.
28. Morath C, Mueller M, Goldschmidt H, et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15: 1582.
29. Kinlen LJ, Sheil AGR, Peto J, et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979; 2: 1461.
30. Andrés A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 2005; 56: 71.
31. Koehl GE, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319.
32. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917.
33. Yarchoan R, Little RF. Immunosuppression-related malignancies. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia: Lippincott William & Wilkins; 2001: 2575.
34. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289.
35. Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221.
36. Mihalov ML, Gattuso P, Abraham K, et al. Incidence of posttransplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996; 10: 248.
37. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2003; 4: 222.
38. Roithmaier S, Haydon AM, Loi S, et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant 2007; 26: 845.
39. Gjertson DW, Dabrowska DM, Cui X, et al. Four causes of cadaveric kidney transplant failure: a competing risk analysis. Am J Transplant 2002; 2: 84.
40. Nyrén O, McLaughlin JK, Gridley G, et al. Cancer risk after hip replacement with metal implants: a population-based cohort study in Sweden. J Natl Cancer Inst 1995; 87: 28.
41. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.
42. Nilsson AC, Spetz CL, Carsjö K, et al. Slutenva°rdsregistrets tillförlitlighet. Diagnosuppgifterna bättre än sitt rykte. [Reliability of the hospital registry. The diagnostic data are better than their reputation]. Läkartidningen 1994; 91: 598.
43. Socialstyrelsen (The Swedish National Board of Health and Welfare). The National Patient Register 2009. Available from: http://www.socialstyrelsen.se/ register/halsodataregister/patientregistret/inenglish [cited 2011].
44. Socialstyrelsen (The Swedish National Board of Health and Welfare). Kodningskvalitet i patientregistret: Slutenva°rd 2008. Stockholm, Sweden, 2010. Publication No. 2010-6-27.
45. Socialstyrelsen (The Swedish National Board of Health and Welfare). Swedish Cancer Registry. Available from: http://www.socialstyrelsen. se/register/halsodataregister/cancerregistret/inenglish. [cited 2011 Aug 31].
46. Socialstyrelsen (The Swedish National Board of Health and Welfare). Dödsorsaksstatistik: Historik, produktionsmetoder och tillförlitlighet [Cause of Death Statistics: History, ProductionMethods and Reliability]. Stockholm, Sweden: 2010. Available at: http://www.socialstyrelsen.se/ publikationer2010/2010-4-33. Accessed May 24, 2013.